1. Home
  2. OXBR vs APVO Comparison

OXBR vs APVO Comparison

Compare OXBR & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oxbridge Re Holdings Limited

OXBR

Oxbridge Re Holdings Limited

N/A

Current Price

$0.89

Market Cap

7.1M

Sector

Finance

ML Signal

N/A

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$4.28

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OXBR
APVO
Founded
2013
2016
Country
Cayman Islands
United States
Employees
3
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
8.3M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
OXBR
APVO
Price
$0.89
$4.28
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$5.00
N/A
AVG Volume (30 Days)
9.8K
35.6K
Earning Date
05-11-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.13
EPS
N/A
N/A
Revenue
N/A
$3,114,000.00
Revenue This Year
$497.99
N/A
Revenue Next Year
$42.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.76
$0.25
52 Week High
$2.85
$13.11

Technical Indicators

Market Signals
Indicator
OXBR
APVO
Relative Strength Index (RSI) 42.26 34.02
Support Level $0.76 $3.95
Resistance Level $0.95 $7.65
Average True Range (ATR) 0.06 0.36
MACD 0.01 -0.02
Stochastic Oscillator 54.02 20.72

Price Performance

Historical Comparison
OXBR
APVO

About OXBR Oxbridge Re Holdings Limited

Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: